




- (72) MAFFRAND, JEAN-PIERRE, FR  
(72) SOUBRIE, PHILIPPE, FR  
(72) TERRANOVA, JEAN-PAUL, FR  
(71) SANOFI-SYNTHELABO, FR  
(51) Int.Cl.<sup>6</sup> A61K 31/645, A61K 31/445  
(30) 1997/11/14 (97/14324) FR  
(30) 1997/11/14 (97/14322) FR

- (54) **ASSOCIATION DE PRINCIPES ACTIFS, NOTAMMENT DE  
TETRAHYDROPYRIDINES ET D'AGENTS INHIBITEURS DE  
L'ACETYLCHOLINESTERASE, POUR LE TRAITEMENT DE  
LA DEMENCE SENILE DU TYPE ALZHEIMER**  
(54) **COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR  
OF TETRAHYDROPYRIDINS AND  
ACETYLCHOLINESTERASE INHIBITING AGENTS, FOR  
TREATING SENILE DEMENTIA SUCH AS ALZHEIMER  
DEMENTIA**



(57) L'invention concerne une composition pharmaceutique contenant en tant que principes actifs un composant (a) choisi entre la 1-(2-napht-2-yléthyl)-4-(3-trifluorométhylphenyl)-1,2,3,6-tétrahydropyridine et un composé (I) dans laquelle Y représente -CH- ou -N-; R<sub>1</sub> représente l'hydrogène, un halogène, un groupe CF<sub>3</sub>, (C<sub>3</sub>-C<sub>4</sub>)alkyle ou (C<sub>1</sub>-C<sub>4</sub>)alcoxyle; R<sub>2</sub> représente l'hydrogène, un halogène, un hydroxyle, un groupe CF<sub>3</sub>, (C<sub>3</sub>-C<sub>4</sub>)alkyle ou (C<sub>1</sub>-C<sub>4</sub>)alcoxyle; R<sub>3</sub> et R<sub>4</sub> représentent chacun l'hydrogène ou un (C<sub>1</sub>-C<sub>3</sub>)alkyle; X représente (a) un (C<sub>3</sub>-C<sub>6</sub>)alkyle; un (C<sub>3</sub>-C<sub>6</sub>)alcoxyle; un (C<sub>3</sub>-C<sub>7</sub>)carboxyalkyle; un (C<sub>1</sub>-C<sub>4</sub>)alkoxycarbonyl(C<sub>3</sub>-C<sub>6</sub>)alkyle; un (C<sub>3</sub>-C<sub>7</sub>)carboxyalkoxyle; ou un (C<sub>1</sub>-C<sub>4</sub>)alkoxycarbonyl(C<sub>3</sub>-C<sub>6</sub>)alkoxyle; (b) un radical choisi parmi un (C<sub>3</sub>-C<sub>7</sub>)cycloalkyle,

(57) The invention concerns a pharmaceutical composition containing as active principles: a constituent (a) selected between 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin and a compound (I) in which: Y represents -CH- or -N-; R<sub>1</sub> represents hydrogen, a halogen, a hydroxyl, a CF<sub>3</sub>, a (C<sub>3</sub>-C<sub>4</sub>)alkyl or (C<sub>1</sub>-C<sub>4</sub>)alkoxyl group; R<sub>2</sub> represents hydrogen, a halogen, a hydroxyl, a CF<sub>3</sub>, (C<sub>3</sub>-C<sub>4</sub>)alkyl or (C<sub>1</sub>-C<sub>4</sub>)alkoxyl group; R<sub>3</sub> and R<sub>4</sub> represent each hydrogen or a (C<sub>1</sub>-C<sub>4</sub>)alkyl; X represents (a) a (C<sub>3</sub>-C<sub>6</sub>)alkyl; a (C<sub>3</sub>-C<sub>6</sub>)alkoxyl; a (C<sub>3</sub>-C<sub>7</sub>)carboxyalkyl; a (C<sub>1</sub>-C<sub>4</sub>)alkoxycarbonyl(C<sub>3</sub>-C<sub>6</sub>)alkyl; a (C<sub>3</sub>-C<sub>7</sub>)carboxyalkoxyl; or a (C<sub>1</sub>-C<sub>4</sub>)alkoxycarbonyl(C<sub>3</sub>-C<sub>6</sub>)alkoxyl; (b) a radical selected among a (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl,





(C<sub>3</sub>-C<sub>7</sub>)cycloalkyloxy, (C<sub>3</sub>-C<sub>7</sub>)cycloalkylméthyle, (C<sub>3</sub>-C<sub>7</sub>)cycloalkylamino et cyclohexényle, ledit radical pouvant être substitué par un halogène, hydroxy, (C<sub>1</sub>-C<sub>4</sub>)alcoxy, carboxy, (C<sub>1</sub>-C<sub>4</sub>)alkoxycarbonyle, amino, mono- ou di-(C<sub>1</sub>-C<sub>4</sub>)alkylamino; ou (c) un groupe choisi parmi phényle, phénoxy, phénylamino, N-(C<sub>1</sub>-C<sub>3</sub>)alkyl-phényl-amino, phénylméthyl, phényléthyle, phénylcarbonyle, phénylthio, phénylsulphonyl, phénylsulphinyle et styryle, ledit groupe pouvant être mono- ou polysubstitué sur le groupe phényle par un halogène, CF<sub>3</sub>, (C<sub>1</sub>-C<sub>4</sub>)alkyle, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, cyano, amino, mono- ou di-(C<sub>1</sub>-C<sub>4</sub>)alkylamino, (C<sub>1</sub>-C<sub>4</sub>)acylamino, carboxy, (C<sub>1</sub>-C<sub>4</sub>)alkoxycarbonyle, aminocarbonyle, mono- ou di-(C<sub>1</sub>-C<sub>4</sub>)alkylaminocarbonyle, amino(C<sub>1</sub>-C<sub>4</sub>)alkyle, hydroxy(C<sub>1</sub>-C<sub>4</sub>)alkyle ou halogéno(C<sub>1</sub>-C<sub>4</sub>)alkyle; éventuellement sous la forme de l'un de ses sels pharmaceutiquement acceptables, et un composant (b) actif dans le traitement symptomatique de la DAT, éventuellement sous la forme de l'un de ses sels pharmaceutiquement acceptables, à la condition que lorsque le composant (a) est autre que la 1-(2-napht-2-yléthyl)-4-(3-trifluorométhylphényl)-1,2,3,6-tétrahydropyridine ou l'un de ses sels pharmaceutiquement acceptables, le composant (b) est un agent inhibiteur de l'acétylcholinestérase.

(C<sub>3</sub>-C<sub>7</sub>)cycloalkyloxy, (C<sub>3</sub>-C<sub>7</sub>)cycloalkylmethyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkylamino and cyclohexenyl, said radical capable of being substituted by a halogen, hydroxy, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, carboxy, (C<sub>1</sub>-C<sub>4</sub>)alkoxycarbonyl, amino, mono- or di-(C<sub>1</sub>-C<sub>4</sub>)alkylamino or (c) a group selected among phenyl, phenoxy, phenylamino, N-(C<sub>1</sub>-C<sub>3</sub>)alkyl-phenyl-amino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulphonyl, phenylsulphinyl and styryl, said group capable of being mono- or polysubstituted on the phenyl group by a halogen, CF<sub>3</sub>, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, cyano, amino, mono- or di-(C<sub>1</sub>-C<sub>4</sub>)alkylamino, (C<sub>1</sub>-C<sub>4</sub>)acylamino, carboxy, (C<sub>1</sub>-C<sub>4</sub>)alkoxycarbonyl, aminocarbonyl, mono- or di-(C<sub>1</sub>-C<sub>4</sub>)alkylaminocarbonyl, amino(C<sub>1</sub>-C<sub>4</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>4</sub>)alkyl, or halogeno(C<sub>1</sub>-C<sub>4</sub>)alkyl; optionally in the form of one of its pharmaceutically acceptable salts; and an constituent (b) active in the symptomatic treatment of DAT, optionally in the form of one of its pharmaceutically acceptable salts, provided that when constituent (a) is other than 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin or one of its pharmaceutically acceptable salts, the constituent (b) is an acetylcholinesterase inhibiting agent.

PCT


ORGANISATION MONDIALE DE LA PROPRIÉTÉ INTELLECTUELLE  
Bureau international

DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITE DE COOPERATION EN MATIÈRE DE BREVETS (PCT)

(51) Classification internationale des brevets <sup>6</sup> : <b>A61K 31/645, 31/445</b>	<b>A1</b>	(11) Numéro de publication internationale: <b>WO 99/25363</b> (43) Date de publication internationale: 27 mai 1999 (27.05.99)
<p>(21) Numéro de la demande internationale: PCT/FR98/02384</p> <p>(22) Date de dépôt international: 9 novembre 1998 (09.11.98)</p> <p>(30) Données relatives à la priorité:            97/14322 14 novembre 1997 (14.11.97) FR            97/14324 14 novembre 1997 (14.11.97) FR</p> <p>(71) Déposant (pour tous les Etats désignés sauf US): SANOFI [FR/FR]; 174, avenue de France, F-75013 Paris (FR).</p> <p>(72) Inventeurs; et            (75) Inventeurs/Déposants (US seulement): MAFFRAND, Jean-Pierre [FR/FR]; 5, rue du Corps Franc Pomiès, F-31120 Portet (FR). SOUBRIE, Philippe [FR/FR]; Le Rey, Valflaunès, F-34270 Saint Mathieu de Treviers (FR). TERRANOVA, Jean-Paul [FR/FR]; 210, traverse du Cardinal, F-34980 Saint Gely du Fesc (FR).</p> <p>(74) Représentant commun: SANOFI; Service Brevets, 174, avenue de France, F-75013 Paris (FR).</p>	<p>(81) Etats désignés: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, brevet ARIPO (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), brevet eurasien (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevet européen (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), brevet OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Publiée  <i>Avec rapport de recherche internationale.</i></p>	

(54) Title: COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR OF TETRAHYDROPYRIDINS AND ACETYLCHOLINESTERASE INHIBITING AGENTS, FOR TREATING SENILE DEMENTIA SUCH AS ALZHEIMER DEMENTIA

(54) Titre: ASSOCIATION DE PRINCIPES ACTIFS, NOTAMMENT DE TETRAHYDROPYRIDINES ET D'AGENTS INHIBITEURS DE L'ACETYLCHOLINESTERASE, POUR LE TRAITEMENT DE LA DEMENCE SENILE DU TYPE ALZHEIMER



## (57) Abstract

The invention concerns a pharmaceutical composition containing as active principles: a constituent (a) selected between 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin and a compound (I) in which: Y represents -CH- or -N-; R<sub>1</sub> represents hydrogen, a halogen, a hydroxyl, a CF<sub>3</sub>, a (C<sub>3</sub>-C<sub>4</sub>) alkyl or (C<sub>1</sub>-C<sub>4</sub>) alkoxy group; R<sub>2</sub> represents hydrogen, a halogen, a hydroxyl, a CF<sub>3</sub>, (C<sub>3</sub>-C<sub>4</sub>) alkyl or (C<sub>1</sub>-C<sub>4</sub>) alkoxy group; R<sub>3</sub> and R<sub>4</sub> represent each hydrogen or a (C<sub>1</sub>-C<sub>4</sub>) alkyl; X represents (a) a (C<sub>3</sub>-C<sub>6</sub>) alkyl; a (C<sub>3</sub>-C<sub>6</sub>) alkoxy; a (C<sub>3</sub>-C<sub>7</sub>) carboxyalkyl; a (C<sub>1</sub>-C<sub>4</sub>) alkoxy carbonyl (C<sub>3</sub>-C<sub>6</sub>-) alkyl; a (C<sub>3</sub>-C<sub>7</sub>) carboxyalkoxy; or a (C<sub>1</sub>-C<sub>4</sub>) alkoxy carbonyl (C<sub>3</sub>-C<sub>6</sub>) alkoxy; (b) a radical selected among a (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>) cycloalkyloxy, (C<sub>3</sub>-C<sub>7</sub>) cycloalkylmethyl, (C<sub>3</sub>-C<sub>7</sub>) cycloalkylamino and cyclohexenyl, said radical capable of being substituted by a halogen, hydroxy, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, carboxy, (C<sub>1</sub>-C<sub>4</sub>) alkoxy carbonyl, amino, mono- or di-(C<sub>1</sub>-C<sub>4</sub>) alkylamino or (c) a group selected among phenyl, phenoxy, phenylamino, N-(C<sub>1</sub>-C<sub>3</sub>) alkyl-phenyl-amino, phenylmethyl, phenylethyl, p henylcarbonyl, phenylthio, phenylsulphonyl, phenylsulphinyl and styryl, said group capable of being mono- or polysubstituted on the phenyl group by a halogen, CF<sub>3</sub>, (C<sub>1</sub>-C<sub>4</sub>) alkyl, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, cyano, amino, mono- or di-(C<sub>1</sub>-C<sub>4</sub>) alkylamino, (C<sub>1</sub>-C<sub>4</sub>) acylamino, carboxy, (C<sub>1</sub>-C<sub>4</sub>) alkoxy carbonyl, aminocarbonyl, mono- or di-(C<sub>1</sub>-C<sub>4</sub>) alkylaminocarbonyl, amino(C<sub>1</sub>-C<sub>4</sub>) alkyl, hydroxy(C<sub>1</sub>-C<sub>4</sub>) alkyl, or halogeno(C<sub>1</sub>-C<sub>4</sub>) alkyl; optionally in the form of one of its pharmaceutically acceptable salts; and an constituent (b) active in the symptomatic treatment of DAT, optionally in the form of one of its pharmaceutically acceptable salts, provided that when constituent (a) is other than 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin or one of its pharmaceutically acceptable salts, the constituent (b) is an acetylcholinesterase inhibiting agent.

**(57) Abrégé**

L'invention concerne une composition pharmaceutique contenant en tant que principes actifs un composant (a) choisi entre la 1-(2-napht-2-yléthyl)-4-(3-trifluorométhylphényl)-1,2,3,6-tétrahydropyridine et un composé (I) dans laquelle Y représente -CH- ou -N-; R<sub>1</sub> représente l'hydrogène, un halogène, un groupe CF<sub>3</sub>, (C<sub>3</sub>-C<sub>4</sub>)alkyle ou (C<sub>1</sub>-C<sub>4</sub>)alkoxyle; R<sub>2</sub> représente l'hydrogène, un halogène, un hydroxyle, un groupe CF<sub>3</sub>, (C<sub>3</sub>-C<sub>4</sub>)alkyle ou (C<sub>1</sub>-C<sub>4</sub>)alkoxyle; R<sub>3</sub> et R<sub>4</sub> représentent chacun l'hydrogène ou un (C<sub>1</sub>-C<sub>3</sub>)alkyle; X représente (a) un (C<sub>3</sub>-C<sub>6</sub>)alkyle; un (C<sub>3</sub>-C<sub>6</sub>)alkoxyle; un (C<sub>3</sub>-C<sub>7</sub>)carboxyalkyle; un (C<sub>1</sub>-C<sub>4</sub>)alkoxycarbonyl(C<sub>3</sub>-C<sub>6</sub>)alkyle; un (C<sub>3</sub>-C<sub>7</sub>)carboxyalkoxyle; ou un (C<sub>1</sub>-C<sub>4</sub>)alkoxycarbonyl(C<sub>3</sub>-C<sub>6</sub>)alkoxyle; (b) un radical choisi parmi un (C<sub>3</sub>-C<sub>7</sub>)cycloalkyle, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyloxy, (C<sub>3</sub>-C<sub>7</sub>)cycloalkylméthyle, (C<sub>3</sub>-C<sub>7</sub>)cycloalkylamino et cyclohexényle, ledit radical pouvant être substitué par un halogène, hydroxy, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, carboxy, (C<sub>1</sub>-C<sub>4</sub>)alkoxycarbonyl, amino, mono- ou di-(C<sub>1</sub>-C<sub>4</sub>)alkylamino; ou (c) un groupe choisi parmi phényle, phénoxy, phénylamino, N-(C<sub>1</sub>-C<sub>3</sub>)alkyl-phényl-amino, phénylméthyl, phényléthyle, phénylcarbonyl, phénylthio, phénylsulphonyl, phénylsulphinyle et styryle, ledit groupe pouvant être mono- ou polysubstitué sur le groupe phényle par un halogène, CF<sub>3</sub>, (C<sub>1</sub>-C<sub>4</sub>)alkyle, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, cyano, amino, mono- ou di-(C<sub>1</sub>-C<sub>4</sub>)alkylamino, (C<sub>1</sub>-C<sub>4</sub>)acylamino, carboxy, (C<sub>1</sub>-C<sub>4</sub>)alkoxycarbonyl, aminocarbonyl, mono- ou di-(C<sub>1</sub>-C<sub>4</sub>)alkylaminocarbonyl, amino(C<sub>1</sub>-C<sub>4</sub>)alkyle, hydroxy(C<sub>1</sub>-C<sub>4</sub>)alkyle ou halogéno(C<sub>1</sub>-C<sub>4</sub>)alkyle; éventuellement sous la forme de l'un de ses sels pharmaceutiquement acceptables, et un composant (b) actif dans le traitement symptomatique de la DAT, éventuellement sous la forme de l'un de ses sels pharmaceutiquement acceptables, à la condition que lorsque le composant (a) est autre que la 1-(2-napht-2-yléthyl)-4-(3-trifluorométhylphényl)-1,2,3,6-tétrahydropyridine ou l'un de ses sels pharmaceutiquement acceptables, le composant (b) est un agent inhibiteur de l'acétylcholinestérase.

**UNIQUEMENT A TITRE D'INFORMATION**

Codes utilisés pour identifier les Etats parties au PCT, sur les pages de couverture des brochures publiant des demandes internationales en vertu du PCT.

AL	Albanie	ES	Espagne	LS	Lesotho	SI	Slovénie
AM	Arménie	FI	Finlande	LT	Lituanie	SK	Slovaquie
AT	Autriche	FR	France	LU	Luxembourg	SN	Sénégal
AU	Australie	GA	Gabon	LV	Lettonie	SZ	Swaziland
AZ	Azerbaïdjan	GB	Royaume-Uni	MC	Monaco	TD	Tchad
BA	Bosnie-Herzégovine	GE	Géorgie	MD	République de Moldova	TG	Togo
BB	Barbade	GH	Ghana	MG	Madagascar	TJ	Tadjikistan
BE	Belgique	GN	Guinée	MK	Ex-République yougoslave de Macédoine	TM	Turkménistan
BF	Burkina Faso	GR	Grèce	ML	Mali	TR	Turquie
BG	Bulgarie	HU	Hongrie	MN	Mongolie	TT	Trinité-et-Tobago
BJ	Bénin	IE	Irlande	MR	Mauritanie	UA	Ukraine
BR	Brésil	IL	Israël	MW	Malawi	UG	Ouganda
BY	Bélarus	IS	Islande	MX	Mexique	US	Etats-Unis d'Amérique
CA	Canada	IT	Italie	NE	Niger	UZ	Ouzbékistan
CF	République centrafricaine	JP	Japon	NL	Pays-Bas	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norvège	YU	Yougoslavie
CH	Suisse	KG	Kirghizistan	NZ	Nouvelle-Zélande	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	République populaire démocratique de Corée	PL	Pologne		
CM	Cameroun	KR	République de Corée	PT	Portugal		
CN	Chine	KZ	Kazakstan	RO	Roumanie		
CU	Cuba	LC	Sainte-Lucie	RU	Fédération de Russie		
CZ	République tchèque	LI	Liechtenstein	SD	Soudan		
DE	Allemagne	LK	Sri Lanka	SE	Suède		
DK	Danemark	LR	Libéria	SG	Singapour		
EE	Estonie						

The object of the present invention is a pharmaceutical composition containing a novel combination of active ingredients for the treatment of senile dementia of the Alzheimer type, constituted of 1,2,3,6-tetrahydropyridine derivatives, optionally in the form of one of their pharmaceutically acceptable salts and a substance active in the symptomatic treatment of senile dementia of the Alzheimer type, in particular an acetylcholinesterase inhibitor, optionally in the form of one of its pharmaceutically acceptable salts and its use for the preparation of medicines designed for the treatment of senile dementia of the Alzheimer type.

Senile dementia of the Alzheimer type designated hereafter DAT ("dementia of the Alzheimer type") is a neurodegenerative disease characterized clinically by the progressive degeneration of cognitive functions, occurring in elderly people with an incidence which increases with age. In the light of demographic trends DAT will become an increasingly widespread disease.

A reduction of the level of several neurotransmitters, of acetylcholine in particular, has been observed in patients suffering from DAT

The only treatment for DAT currently available commercially consists of administering acetylcholinesterase inhibitors which by reducing the hydrolysis of acetylcholine thus increase its bioavailability. Hence it is a symptomatic treatment.

Tacrine, marketed under the trade mark COGNEX<sup>®</sup>, and donepezil, sold under the trade mark ARICEPT<sup>®</sup>, are acetylcholinesterase inhibitors indicated for the symptomatic treatment of mild to moderate forms of DAT. Other products for the symptomatic treatment of DAT are under study. Some of them also act on the availability of acetylcholine, others improve the symptomatology of patients suffering from DAT by other mechanisms. Hitherto, no commercially available medicine has proved capable of slowing the progression of the disease.

EP-458696 describes the use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine, designated in the literature SR 57746, for the preparation of medicines designed to combat neurodegenerative states, including senile dementia and Alzheimer's disease. The neurotrophic action of SR 57746 on the nervous system is similar to that of certain endogenous neurotrophins such as, for example, the nerve growth factor (NGF).


WO 97/01536 describes novel 4-substituted 1-phenylalkyl-1,2,3,6-tetrahydropyridines having a neuroprotective and neurotrophic activity similar to that of certain endogenous neurotrophins. As a result of this activity, it is presumed that the compounds described in this patent application will be useful in the treatment of several diseases of the central nervous system, including Alzheimer's disease.

The activity of the compound SR 57746 and the compounds described in WO 97/01536 in the treatment of the nervous diseases such as DAT is not designed to treat the symptoms but, by protecting the neurones, to modify the course of the disease and to reduce its progression.

It has now been found that the combination of the above compounds, optionally in the form of one of their pharmaceutically acceptable salts, with a compound active in the symptomatic treatment of senile dementia of the Alzheimer type, in particular an acetylcholinesterase inhibitor, optionally in the form of one of its pharmaceutically acceptable salts, leads to a complete and very efficacious treatment of DAT, the combination exerting a rapid and complementary effect.

Thus, the object of the present invention is a pharmaceutical composition containing as active ingredients

- a compound (a) selected from 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine and a compound of formula (I) :



in which

Y is -CH- or -N-;

R<sub>1</sub> hydrogen, halogen, a CF<sub>3</sub>, (C<sub>3</sub>-C<sub>4</sub>) alkyl or (C<sub>1</sub>-C<sub>4</sub>)  
5 alkoxy group;

R<sub>2</sub> is hydrogen, halogen, hydroxyl, CF<sub>3</sub>, (C<sub>3</sub>-C<sub>4</sub>) alkyl or  
(C<sub>1</sub>-C<sub>4</sub>) alkoxy group;

R<sub>3</sub> and R<sub>4</sub> each is hydrogen or (C<sub>1</sub>-C<sub>3</sub>) alkyl;

X is

10 (a) (C<sub>3</sub>-C<sub>6</sub>) alkyl; (C<sub>3</sub>-C<sub>6</sub>) alkoxy; (C<sub>3</sub>-C<sub>7</sub>) carboxyalkyl;  
(C<sub>1</sub>-C<sub>4</sub>) alkoxy carbonyl (C<sub>3</sub>-C<sub>6</sub>) alkyl; (C<sub>3</sub>-C<sub>7</sub>)  
carboxyalkoxy; or (C<sub>1</sub>-C<sub>4</sub>) alkoxy carbonyl (C<sub>3</sub>-C<sub>6</sub>) alkoxy;

(b) a radical selected from (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)  
cycloalkyloxy, (C<sub>3</sub>-C<sub>7</sub>) cycloalkylmethyl, (C<sub>3</sub>-C<sub>7</sub>)  
15 cycloalkylamino and cyclohexenyl, said radical being  
optionally substituted by halogen, hydroxy, (C<sub>1</sub>-C<sub>4</sub>)  
alkoxy, carboxy, (C<sub>1</sub>-C<sub>4</sub>) alkoxy carbonyl, amino, mono or  
di-(C<sub>1</sub>-C<sub>4</sub>) alkylamino; or

(c) a group selected from phenyl, phenoxy, phenylamino, N-  
20 (C<sub>1</sub>-C<sub>3</sub>) alkylphenylamino, phenylmethyl, phenylethyl,  
phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl  
or styryl, said phenyl group being optionally mono- or  
polysubstituted by halogen, CF<sub>3</sub>, (C<sub>1</sub>-C<sub>4</sub>) alkyl, (C<sub>1</sub>-C<sub>4</sub>)  
alkoxy, cyano, amino, mono- or di-(C<sub>1</sub>-C<sub>4</sub>) alkylamino, (C<sub>1</sub>-  
25 C<sub>4</sub>) acylamino, carboxy, (C<sub>1</sub>-C<sub>4</sub>) alkoxy carbonyl,  
aminocarbonyl, mono- or di-(C<sub>1</sub>-C<sub>4</sub>) alkylaminocarbonyl,  
amino (C<sub>1</sub>-C<sub>4</sub>) alkyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>) alkyl or halogeno  
(C<sub>1</sub>-C<sub>4</sub>) alkyl;

optionally in the form of one of its pharmaceutically  
30 acceptable salts

and

- a compound (b) active in the symptomatic treatment of DAT, optionally in the form of one of its pharmaceutically acceptable salts provided that when compound (a) is other than 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine or one of its pharmaceutically acceptable salts, compound (b) is an acetylcholinesterase inhibitor.

1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine (SR 57746) was described in EP 101 381 and the compounds of formula (I) above are described in WO 97/01536.

A particularly advantageous compound (a) is 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine (SR 57746), optionally in the form of one of its pharmaceutically acceptable salts.

Of the pharmaceutically acceptable salts of SR 57746, the hydrochloride designated hereafter SR 57746A is a particularly preferred salt.

An advantageous method for the preparation of SR 57746A consists of the reaction between 2-(2-bromoethyl)naphthalene and 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine and the isolation of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine hydrochloride which is then crystallized from an ethanol/water mixture by heating and cooling to 5°C with a rate of cooling of 10°C/hour and a stirring speed of 400 revolutions/minute, so as to obtain a mixture of two crystalline forms in a ratio of about 66/34.

SR 57746A is preferably used in a microparticulate form, for example in an essentially amorphous form obtained by spray drying or in a microcrystalline form by micronization.

Another particularly advantageous compound (a) is 1-{2-(4-biphenylyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydro-pyridine, in particular its hydrochloride salt.

Other advantageous compounds are the following :

- 1-{2-(3'-chloro-4-biphenyl) ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(2'-chloro-4-biphenyl) ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
5 1-{2-(4'-chloro-4-biphenyl) ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(4'-fluoro-4-biphenyl) ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
10 1-{2-(3'-trifluoromethyl-4-biphenyl) ethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(4-cyclohexylphenyl) ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(4-biphenyl) ethyl}-4-(4-fluorophenyl)-1,2,3,6-tetrahydro-pyridine;  
15 1-{2-(4-biphenyl)-2-methylpropyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(4-phenoxyphenyl) ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(4-benzylphenyl) ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
20 1-{2-(4-n-butylphenyl) ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(4-n-butoxyphenyl) ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
25 1-{2-(4-(4-ethoxycarbonylpropoxy) phenyl) ethyl}-4-(3-trifluoro-methylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(4-biphenyl) ethyl}-4-(6-chloropyrid-2-yl)-1,2,3,6-tetrahydro-pyridine;  
1-{2-(2,3'-dichloro-4-biphenyl) ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
30 1-{2-(3-chloro-4-biphenyl) ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(3',5'-dichloro-4-biphenyl) ethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;  
35 1-{2-(2',4'-dichloro-4-biphenyl) ethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(2-chloro-4-biphenyl) ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;

1-{2-(3'-chloro-4-biphenyl)-2-methylpropyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(2-fluoro-4-biphenyl)propyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 5 1-{2-(4-methoxy-3-biphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(4'-methoxy-4-biphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 10 1-{2-(4'-hydroxy-4-biphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(4'-ethoxycarbonylbutoxy-4-biphenyl)ethyl}-4-(3-trifluoro-methylphenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(3-biphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 15 1-{2-(3'-chloro-4'-fluoro-4-biphenyl)ethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(2'-trifluoromethyl-4-biphenyl)ethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(3,4-diisobutylphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 20 1-{2-(3,4-dipropylphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(4-cyclohexylphenyl)ethyl}-4-(6-chloropyrid-2-yl)-1,2,3,6-tetrahydropyridine;  
 25 1-{2-(4-isobutylphenyl)propyl}-4-(6-chloropyrid-2-yl)-1,2,3,6-tetrahydropyridine;  
 and their pharmaceutically acceptable salts.

In the present description, the expression "compound active in the symptomatic treatment of DAT" designates a product which is capable of improving the symptomatology of patients suffering from DAT without having an effect on the causes of the disease.

Such compounds are, for example, acetylcholinesterase inhibitors, M<sub>1</sub> muscarinic agonists, nicotinic agonists N-methyl-D-aspartate (NMDA) receptor antagonists, nootropics, the acetylcholinesterase inhibitors being particularly advantageous.

In accordance with a preferred feature, the invention relates to a pharmaceutical composition containing as active ingredient a compound (a), optionally in the form of one of its pharmaceutically acceptable salts and a  
5 compound (b) selected from the acetylcholinesterase inhibitors, optionally in the form of one of its pharmaceutically acceptable salts.

Particularly advantageous acetylcholinesterase inhibitors are tacrine and donepezil.

10 Other acetylcholinesterase inhibitors which may be used are for example rivastigmine (SDZ-ENA-713), galanthamine, metrifonate, eptastigmine, velnacrine, physostigmine (Drugs, 1997, 53 (5): 752-768; The Merck Index 12 ed.).

15 Other acetylcholinesterase inhibitors are 5,7-dihydro-3-{2-(1-(phenylmethyl)-4-piperidinyl)ethyl}-6H-pyrrolo (3,2-f)-1,2-benzisoxazol-6-one, also known as icopezil (J. Med. Chem., 1995, 38: 2802-2808), MDL-73,745 or zifrosilone (Eur. J. Pharmacol., 1995, 276: 93-99), TAK-  
20 147 (J. Med. Chem., 1994, 37: 2292-2299).

Other acetylcholinesterase inhibitors are for example those which are described in the patent applications JP 09-095483, WO 97/13754, WO 97/21681, WO 97/19929, ZA 96-04565, US 5,455,245, WO 95-21822, EP 637 586, US  
25 5,401,749, EP 742 207, US 5,547,960, WO 96/20176, WO 96/02524, EP 677 516, JP 07-188177, JP 07-133274, EP 649 846, EP 648 771, JP 07-048370, US 5,391,553, WO 94/29272, EP 627 400.

M<sub>1</sub> receptor antagonists are, for example, milameline,  
30 besipiridine, talsaclidine, xanomeline, YM-796 and YM-954 (Eur. J. Pharmacol., 1990, 187: 479-486), 3-{N-(2-diethylamino-2-methylpropyl)-6-phenyl-5-propyl}-pyridazinamine, also known as SR-46559 (Biorg. Med. Chem. Let., 1992, 2: 833-838), AF-102, CI-979, L-689,660, LU 25-  
35 109, S-99 77-2, SB 202,026, thiopilocarpine, WAL 2014 (Pharmacol. Toxicol., 1996, 78: 59-68).

Advantageous nicotine agonists are for example MKC-231 (Biorg. Med. Chem. Let., 1995, 5 (14): 1495-1500), T-

588 (Japan J. Pharmacol., 1993, 62: 81-86), ABT-418  
(Br.J.Pharmacol., 1997, 120: 429-438).

An advantageous NMDA receptor antagonist is for example memantine (Arzneim. Forsch., 1991, 41: 773-780).

5 In accordance with another feature, the present invention relates to the use of the compositions of the invention for the preparation of medicines designed for the treatment of senile dementia of the Alzheimer type.

10 In accordance with another feature the present invention also relates to another method for the treatment of senile dementia of the Alzheimer type which consists of administering to a patient suffering from this disease an efficacious dose of a compound (a) above, optionally in the form of one of its pharmaceutically acceptable salts  
15 and an efficacious dose of a compound (b), in particular an acetylcholinesterase inhibitor, optionally in the form of one of its pharmaceutically acceptable salts, said administrations being simultaneous, sequential or alternating at intervals and the efficacious doses of the  
20 active ingredients being contained in separate unit forms of administration or, when the active ingredients are administered simultaneously, the two active ingredients being advantageously contained in a single pharmaceutical form.

25 The active ingredients according to the present invention are preferably administered orally.

In the pharmaceutical compositions of the present invention for oral administration, the active ingredients may be administered in unit forms of administration, in a  
30 mixture with standard pharmaceutical vehicles, to animals and to human beings for the treatment of the above-mentioned diseases. The appropriate unit forms of administration include for example optionally divisible tablets, capsules, powders, granules and solutions or oral  
35 suspensions.

When a solid composition is prepared in the form of tablets, the principal active ingredient is mixed with a pharmaceutical vehicle such as gelatin, starch, lactose,

magnesium stearate, talc, gum arabic or the like. The tablets may be coated with sucrose or other suitable materials or they may also be treated so that they have a prolonged or delayed activity and that they continuously  
5 release a predefined quantity of active ingredient.

A preparation of capsules is obtained by mixing the active ingredient with a diluent and by pouring the mixture obtained into soft or hard capsules.

A preparation in the form of a syrup or elixir may  
10 contain the active ingredient together with a sweetening agent, preferably calorie-free, methylparaben and propylparaben as antiseptics as well as a flavouring agent and a suitable colouring matter.

The powders and granules dispersible in water may  
15 contain the active ingredient in a mixture with dispersion agents or wetting agents, or suspension agents like polyvinylpyrrolidone, just as with sweetening agents or flavour correctors.

The active ingredient may also be formulated in the  
20 form of microcapsules, optionally with one or more vehicles or additives.

In the pharmaceutical compositions according to the present invention, the active ingredient may also be in the form of an inclusion complex in cyclodextrins, their  
25 ethers or their esters.

The quantity of active ingredient to be administered depends, as always, on the degree of advancement of the disease as well as on the age and weight of the patient.

The doses of the two active ingredients are similar  
30 to those usually selected in the state of the art for the isolated administration of each of these active ingredients.

The compositions according to the invention thus contain recommended doses for the uncombined treatments,  
35 for example, of 0.5 mg to 700 mg of compound (a) or of one of its pharmaceutically acceptable salts and 0.1 to 50 mg of compound (b) or of one of its pharmaceutically

acceptable salts or even lower doses, given that the combination exerts a synergistic effect.

Advantageous compositions contain for example 0.5 to 5 mg of SR 57746 or one of its pharmaceutically acceptable salts and 0.1 to 50 mg. of an acetylcholinesterase inhibitor or one of its pharmaceutically acceptable salts.

Preferred compositions contain 0.5 to 5 mg of SR 57746 or one of its pharmaceutically acceptable salts, in particular the hydrochloride, and 2 to 10 mg of donepezil or one of its pharmaceutically acceptable salts.

The doses indicated in the present prescription refer to the active ingredients not combined in salt form.

The activity of the composition according to the invention was demonstrated by using a specific model for the septo-hippocampal cholinergic system on lesions caused by the injection of vincristine which induces biochemical alterations similar to the changes present in Alzheimer's disease.

The procedures used in this model, lesions caused by vincristine as well as the evaluation of the social memory are described in EP 655247.

Evaluation test of the social memory in the rat.

After lesions have provoked by injection of vincristine as described in EP 655247 the rats exhibit a stable and durable amnesia. The rats are divided into two groups, one group receiving solvent and the other group receiving SR 57746A at a dose of 5 mg.kg p.o., a dose which is insufficient to permit functional recovery in terms of memory in the rats undergoing this test (the efficacious dose being 10 mg/kg as described in EP 655247). The dose of 1 mg/kg i.p. of tacrine is then administered to the two groups of rats. The control group which has received solvent and tacrine shows no recovery of memory whereas the group which has been treated with SR 57746A (sub-efficacious dose) and tacrine shows a significant recovery of memory retention deficits.


The results of this test indicate a synergistic action of the combination of the present invention.

As a result of this complementary and synergistic effect of the constituents of the combination, simultaneously guaranteeing the protection and even cure of the neurones affected by the disease as well as the  
5 immediate improvement of the symptoms in the patient, the composition of the invention makes possible an efficacious treatment of DAT in all its forms.

CLAIMS

1. A pharmaceutical composition containing as active ingredients

- a compound (a) selected from 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine and a compound of formula (I) :



in which

10 Y is -CH- or -N-;

R<sub>1</sub> is hydrogen, halogen, a CF<sub>3</sub>, (C<sub>3</sub>-C<sub>4</sub>) alkyl or (C<sub>1</sub>-C<sub>4</sub>) alkoxy group;

R<sub>2</sub> is hydrogen, halogen, hydroxyl, CF<sub>3</sub>, (C<sub>3</sub>-C<sub>4</sub>) alkyl or (C<sub>1</sub>-C<sub>4</sub>) alkoxy group;

15 R<sub>3</sub> and R<sub>4</sub> each is hydrogen or (C<sub>1</sub>-C<sub>3</sub>) alkyl;

X is

(a) (C<sub>3</sub>-C<sub>6</sub>) alkyl; (C<sub>3</sub>-C<sub>6</sub>) alkoxy; (C<sub>3</sub>-C<sub>7</sub>) carboxyalkyl; (C<sub>1</sub>-C<sub>4</sub>) alkoxy-carbonyl (C<sub>3</sub>-C<sub>6</sub>) alkyl; (C<sub>3</sub>-C<sub>7</sub>) carboxyalkoxy; or (C<sub>1</sub>-C<sub>4</sub>) alkoxy-carbonyl (C<sub>3</sub>-C<sub>6</sub>) alkoxy;

(b) a radical selected from (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>) cycloalkyloxy, (C<sub>3</sub>-C<sub>7</sub>) cycloalkylmethyl, (C<sub>3</sub>-C<sub>7</sub>) cycloalkylamino and cyclohexenyl, said radical being optionally substituted by halogen, hydroxy, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, carboxy, (C<sub>1</sub>-C<sub>4</sub>) alkoxy-carbonyl, amino, mono or di-(C<sub>1</sub>-C<sub>4</sub>) alkylamino; or

(c) a group selected from phenyl, phenoxy, phenylamino, N-(C<sub>1</sub>-C<sub>3</sub>) alkylphenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl or styryl, said phenyl group being optionally mono- or polysubstituted by halogen, CF<sub>3</sub>, (C<sub>1</sub>-C<sub>4</sub>) alkyl, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, cyano, amino, mono- or di-(C<sub>1</sub>-

C<sub>4</sub>) alkylamino, (C<sub>1</sub>-C<sub>4</sub>) acylamino, carboxy, (C<sub>1</sub>-C<sub>4</sub>)  
alkoxycarbonyl, aminocarbonyl, mono- or di-(C<sub>1</sub>-C<sub>4</sub>)  
alkylaminocarbonyl, amino (C<sub>1</sub>-C<sub>4</sub>) alkyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)  
alkyl or halogeno (C<sub>1</sub>-C<sub>4</sub>) alkyl;

5 optionally in the form of one of its pharmaceutically  
acceptable salts


and

10 - a compound (b) active in the symptomatic treatment  
of DAT, optionally in the form of one of its  
pharmaceutically acceptable salts provided that when  
compound (a) is other than 1-(2-naphth-2-ylethyl)-4-(3-  
trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine or one  
of its pharmaceutically acceptable salts, compound (b) is  
an acetylcholinesterase inhibitor.

15 2. Composition according to Claim 1, characterized  
in that it contains as active ingredients 1-(2-naphth-2-  
ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-  
tetrahydropyridine, optionally in the form of one of its  
pharmaceutically acceptable salts in combination with a  
20 compound active in the symptomatic treatment of senile  
dementia of the Alzheimer type, optionally in the form of  
one of its pharmaceutically acceptable salts.

3. Composition according to Claim 1, characterized  
in that it contains as active ingredients

25 - a compound of formula (I) :



in which

Y is -CH- or -N-;

30 R<sub>1</sub> is hydrogen, halogen, a CF<sub>3</sub>, (C<sub>3</sub>-C<sub>4</sub>) alkyl or (C<sub>1</sub>-C<sub>4</sub>)  
alkoxy group;

R<sub>2</sub> is hydrogen, halogen, hydroxyl, CF<sub>3</sub>, (C<sub>3</sub>-C<sub>4</sub>) alkyl or  
(C<sub>1</sub>-C<sub>4</sub>) alkoxy group;

R<sub>3</sub> and R<sub>4</sub> each is hydrogen or (C<sub>1</sub>-C<sub>3</sub>) alkyl;

X is

(a) (C<sub>3</sub>-C<sub>6</sub>) alkyl; (C<sub>3</sub>-C<sub>6</sub>) alkoxy; (C<sub>3</sub>-C<sub>7</sub>)  
 carboxyalkyl; (C<sub>1</sub>-C<sub>4</sub>) alkoxycarbonyl (C<sub>3</sub>-C<sub>6</sub>) alkyl; (C<sub>3</sub>-  
 C<sub>7</sub>) carboxyalkoxy; or (C<sub>1</sub>-C<sub>4</sub>) alkoxycarbonyl (C<sub>3</sub>-C<sub>6</sub>)  
 5 alkoxy;

(b) a radical selected from (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, (C<sub>3</sub>-  
 C<sub>7</sub>) cycloalkyloxy, (C<sub>3</sub>-C<sub>7</sub>) cycloalkylmethyl, (C<sub>3</sub>-C<sub>7</sub>)  
 cycloalkylamino and cyclohexenyl, said radical being  
 optionally substituted by halogen, hydroxy, (C<sub>1</sub>-C<sub>4</sub>)  
 10 alkoxy, carboxy, (C<sub>1</sub>-C<sub>4</sub>) alkoxycarbonyl, amino, mono or  
 di-(C<sub>1</sub>-C<sub>4</sub>) alkylamino; or

(c) a group selected from phenyl, phenoxy,  
 phenylamino, N-(C<sub>1</sub>-C<sub>3</sub>) alkylphenylamino, phenylmethyl,  
 phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl,  
 15 phenylsulfinyl or styryl, said phenyl group being  
 optionally mono- or polysubstituted by halogen, CF<sub>3</sub>, (C<sub>1</sub>-  
 C<sub>4</sub>) alkyl, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, cyano, amino, mono- or di-(C<sub>1</sub>-  
 C<sub>4</sub>) alkylamino, (C<sub>1</sub>-C<sub>4</sub>) acylamino, carboxy, (C<sub>1</sub>-C<sub>4</sub>)  
 alkoxycarbonyl, aminocarbonyl, mono- or di-(C<sub>1</sub>-C<sub>4</sub>)  
 20 alkylaminocarbonyl, amino (C<sub>1</sub>-C<sub>4</sub>) alkyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)  
 alkyl or halogeno (C<sub>1</sub>-C<sub>4</sub>) alkyl;

optionally in the form of one of its pharmaceutically  
 acceptable salts

and

25 - an acetylcholinesterase inhibitor,

or a pharmaceutically acceptable salt of the latter.

4. Composition according to Claim 3, characterized  
 in that compound (a) is 1-{2-(4-biphenyl)ethyl}-4-(3-  
 trifluoro-methylphenyl)-1,2,3,6-tetrahydropyridine or its  
 30 hydrochloride salt.

5. Composition according to Claim 3, characterized  
 in that compound (a) is selected from the following  
 compounds :

1-{2-(3'-chloro-4-biphenyl)ethyl}-4-(3-  
 35 trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;

- 1-{2-(2'-chloro-4-biphenylyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(4'-chloro-4-biphenylyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
5 1-{2-(4'-fluoro-4-biphenylyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(3'-trifluoromethyl-4-biphenylyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(4-cyclohexylphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
10 1-{2-(4-biphenylyl)ethyl}-4-(4-fluorophenyl)-1,2,3,6-tetrahydro-pyridine;  
1-{2-(4-biphenylyl)-2-methylpropyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
15 1-{2-(4-phenoxyphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(4-benzylphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(4-n-butylphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
20 1-{2-(4-n-butoxyphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(4-(4-ethoxycarbonylpropoxy)phenyl)ethyl}-4-(3-trifluoro-methylphenyl)-1,2,3,6-tetrahydropyridine;  
25 1-{2-(4-biphenylyl)ethyl}-4-(6-chloropyrid-2-yl)-1,2,3,6-tetrahydro-pyridine;  
1-{2-(2,3'-dichloro-4-biphenylyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(3-chloro-4-biphenylyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
30 1-{2-(3',5'-dichloro-4-biphenylyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(2',4'-dichloro-4-biphenylyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
35 1-{2-(2-chloro-4-biphenylyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
1-{2-(3'-chloro-4-biphenylyl)-2-methylpropyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;

1-{2-(2-fluoro-4-biphenyl)propyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(4-methoxy-3-biphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 5 1-{2-(4'-methoxy-4-biphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(4'-hydroxy-4-biphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(4'-ethoxycarbonylbutoxy-4-biphenyl)ethyl}-4-(3-  
 10 trifluoro-methylphenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(3-biphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(3'-chloro-4'-fluoro-4-biphenyl)ethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;  
 15 1-{2-(2'-trifluoromethyl-4-biphenyl)ethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(3,4-diisobutylphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(3,4-dipropylphenyl)ethyl}-4-(3-  
 20 trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(4-cyclohexylphenyl)ethyl}-4-(6-chloropyrid-2-yl)-1,2,3,6-tetrahydropyridine;  
 1-{2-(4-isobutylphenyl)propyl}-4-(6-chloropyrid-2-yl)-1,2,3,6-tetrahydropyridine;  
 25 and their pharmaceutically acceptable salts.

6. Composition according to Claim 1 characterized in that the compound active in the symptomatic treatment of senile dementia of the Alzheimer type is selected from acetylcholinesterase inhibitors, M<sub>1</sub> muscarinic agonists,  
 30 nicotinic agonists, NMDA receptor antagonists and nootropic agents.

7. Composition according to Claim 6, characterized in that compound (b) is an acetylcholinesterase inhibitor.

8. Composition according to Claim 7, characterized  
 35 in that the acetylcholinesterase inhibitor is selected from tacrine and donepezil.

9. Composition according to Claim 7, characterized in that the acetylcholinesterase inhibitor is selected

from rivastigmine, galanthamine, metrifonate, eptastigmine, velnacrine, phystostigmine, icozepil and zifrosilone.

10. Composition according to Claim 1, characterized  
5 in that it contains from 0.5 to 700 mg of compound (a).

11. Composition according to Claim 1, characterized in that it contains from 0.1 to 50 mg of compound (b).

12. Composition according to Claim 2, characterized in that it contains from 0.5 to 10 mg of 1-(2-naphth-2-  
10 ylethyl)-4-(3-trifluoro-methylphenyl)-1,2,3,6-tetrahydropyridine.

13. Composition according to Claim 2, characterized in that it contains as active ingredients 1-(2-naphth-2-  
15 ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine and donepezil or their pharmaceutically acceptable salts.

14. Composition according to Claim 3, characterized in that it contains as active ingredients 1-{2-(4-  
20 biphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine and donepezil or their pharmaceutically acceptable salts.

15. Composition according to Claim 2 containing 0.5 to 5 mg of 1-(2-naphth-2-ylethyl)-4-(3-  
25 trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine and 2 to 10 mg of donepezil.

16. Composition according to any one of the preceding Claims for the treatment of senile dementia of the Alzheimer type.

17. Use of the composition according to any one of  
30 the preceding Claims for the preparation of medicines designed for the treatment of senile dementia of the Alzheimer type.

18. Use according to Claim 17, characterized in that the compound (a) is selected from 1-(2-naphth-2-ylethyl)-  
35 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine and 1-{2-(4-biphenyl)ethyl}-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine.

19. Use according to Claim 17, characterized in that the compound (b) is selected from tacrine and donepezil.